What it’s like to be the serious company in an often absurd room
The past few years have seen cannabidiol, or CBD, go from a fairly obscure little compound to a hazily regulated product marketed as a solution for pain, anxiety, and myriad other maladies.
Watching from the sidelines has been GW Pharmaceuticals, a traditional drug company that has “very much played by the rules” on the way to winning the first-ever FDA approval for a CBD-based therapeutic, CEO Justin Gover told STAT.
That meant spending decades on research and then going through the rigorous process of FDA review, which led to last year’s approval of Epidiolex to treat two rare and devastating forms of epilepsy. Now, as GW presses forward with more CBD-derived therapeutics, Gover welcomes the sudden influx of interest in cannabinoid treatments — albeit with a caveat.
“The only note of caution I would add is when I see companies that are doing some form of research that I would consider more for promotional reasons rather than because they’re serious about drug development,” he said. “That is something I don’t welcome.”
Read more.
Watching from the sidelines has been GW Pharmaceuticals, a traditional drug company that has “very much played by the rules” on the way to winning the first-ever FDA approval for a CBD-based therapeutic, CEO Justin Gover told STAT.
That meant spending decades on research and then going through the rigorous process of FDA review, which led to last year’s approval of Epidiolex to treat two rare and devastating forms of epilepsy. Now, as GW presses forward with more CBD-derived therapeutics, Gover welcomes the sudden influx of interest in cannabinoid treatments — albeit with a caveat.
“The only note of caution I would add is when I see companies that are doing some form of research that I would consider more for promotional reasons rather than because they’re serious about drug development,” he said. “That is something I don’t welcome.”
Read more.
.png)
No hay comentarios:
Publicar un comentario